Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin 10% - Grifols

Drug Profile

Immune globulin 10% - Grifols

Alternative Names: Gammaked; Gamunex; Gamunex-C; Gamunex-IGIV; IGIV; IGIV-C; Intravenous gammaglobulin; IVIG; TAL-05-0002

Latest Information Update: 24 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare
  • Developer Bayer HealthCare; Beth Israel Deaconess Medical Center; Grifols; Kedrion
  • Class Antidementias; Antivirals; Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic inflammatory demyelinating polyradiculoneuropathy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic inflammatory demyelinating polyradiculoneuropathy; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders
  • Phase III Myasthenia gravis
  • Phase II Diabetic neuropathies
  • Discontinued Multiple sclerosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Apr 2018 Grifols Therapeutics completes a phase III trial in Myasthenia gravis in South Africa, Russia, Romania, Latvia, Argentina, Poland, France, Estonia, Canada, Hungary, Czech Republic and Belgium (IV) (NCT02413580) (EudraCT2013-005098-28)
  • 01 Jan 2018 Grifols Therapeutics completes a phase II trial in Myasthenia gravis in USA, Canada, Lithuania, Estonia, Hungary, Czech Republic, Germany, Poland, France and Belgium (IV) (NCT02473952) (EudraCT2014-003997-18)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top